EL7.AI
Mergers & AcquisitionsMediumUpdated×2•Originally published 22 July 2026•Updated 22 July 2026•
1 min read

Repligen to Acquire BioLife Solutions in $1.5 Billion Deal

Key Facts

1Repligen announced the acquisition of BioLife Solutions to strengthen its portfolio in the high-growth cell therapy market.
2The deal adds BioLife's high-margin, recurring revenue business to Repligen's operations.

In a move reflecting the accelerating consolidation within the biotech sector, Repligen has announced a definitive agreement to acquire BioLife Solutions. According to reports, the acquisition is designed to strengthen Repligen's portfolio in the high-growth cell and gene therapy market. BioLife is a specialized provider of biopreservation media, making this integration a strategic step to expand Repligen's technical capabilities.

The deal adds BioLife's high-margin, recurring revenue business to Repligen's broader operations. Repligen aims to fast-track its market leadership by integrating BioLife's differentiated product line. This strategic alignment focuses on capturing value from established biotech supply chains that offer stable and predictable financial returns.

As of July 22, 2026, the acquisition is valued at approximately $1.5 billion and will be executed through a combination of cash and stock. Investors are monitoring the timeline for closing the deal alongside broader economic catalysts such as the U.S. Producer Price Index (PPI), which recently showed a -0.3% monthly change, impacting sentiment for growth-oriented sectors.